Ajanta Pharma

{
  "main_header": {
    "sid": 178818,
    "name": "Ajanta Pharma",
    "stock_name": "Ajanta Pharma",
    "full_name": "Ajanta Pharma Ltd.",
    "name_url": "stocks-analysis/ajanta-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "3,064.20",
    "chg": 29.2,
    "chgp": "0.96%",
    "dir": 1,
    "prev_price": "3,035.00",
    "mcapval": "37,529.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 532331,
    "symbol": "AJANTPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE031B01049",
    "curr_date": "May 11",
    "curr_time": "",
    "bse_nse_vol": "1.03 lacs",
    "exc_status": "Active",
    "traded_date": "May 11, 2026",
    "traded_date_str": "2026 05 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ajanta-pharma-178818-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Ajanta Pharma Gains 4.41%: Key Events and Market Dynamics from 4-8 May 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-gains-441-key-events-and-market-dynamics-from-4-8-may-2026-3984283",
        "imagepath": "",
        "date": "2026-05-10 15:00:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> Week opens at Rs.2,904.15</p>\n                    <p><strong>5 May:</strong> Q4 FY26 results reveal strong topline but margin concerns</p>\n                    <p><strong>6 May:</strong> Intraday high surge to Rs.3,111.5 (+7.24%)</p>\n                    <p><strong>7 May:</strong> Slight pullback to Rs.3,080.20 (-0.42%)</p>\n                    <p><strong>8 May:</strong> Week closes at Rs.3,032.20 (-1.56%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,904.15</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">W..."
      },
      {
        "title": "Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-hold-by-marketsmojo-3979580",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AjantaPharmaLtd_mojoScore_3979580.png",
        "date": "2026-05-07 10:10:27",
        "description": "Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Are Ajanta Pharma Ltd. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ajanta-pharma-ltd-latest-results-good-or-bad-3978379",
        "imagepath": "",
        "date": "2026-05-06 19:15:51",
        "description": "Ajanta Pharma Ltd. reported its Q4 FY26 results, showcasing a strong revenue performance alongside some concerns regarding profitability. The company achieved net sales of ₹1,421.64 crores, reflecting a year-on-year growth of 21.47%, which is significantly higher than the previous year's growth of 11.04%. This marks the highest quarterly revenue in the company's history, indicating robust demand and effective market strategies.\n\nHowever, the financial results also revealed challenges in maintaining profitability. The net profit for the quarter stood at ₹266.70 crores, representing an 18.40% increase year-on-year, yet it experienced a sequential decline of 2.58% from the previous quarter. This decline raises questions about the sustainability of profit levels despite strong sales growth.\n\nA notable concern is the contraction in operating margins, which fell to 23.45% from 27.80% in the previous quarter, indi..."
      },
      {
        "title": "Ajanta Pharma Ltd. Surges 7.24% to Day's High of Rs 3111.5 — Outperforms Sector by 4.72 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-hits-intraday-high-with-724-surge-on-6-may-2026-3977906",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AjantaPharmaLtd_priceRelatedfactors_3977906.png",
        "date": "2026-05-06 12:45:49",
        "description": "The Sensex edged lower by 0.12% on 6 May 2026, while Ajanta Pharma Ltd. surged 7.24%, touching an intraday high of Rs 3111.5. This 4.72-percentage-point outperformance over the Pharmaceuticals &amp; Biotechnology sector’s 2.14% gain highlights a distinctly stock-specific rally rather than a broad market lift."
      },
      {
        "title": "Ajanta Pharma Reports Flat Quarterly Performance Amidst Strong Historical Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-reports-flat-quarterly-performance-amidst-strong-historical-returns-3976643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AjantaPharmaLtd_fintrenddot_3976643.png",
        "date": "2026-05-06 08:00:05",
        "description": "Ajanta Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. Despite achieving its highest-ever quarterly net sales, the company’s overall financial trend score has declined, prompting a reassessment of its market stance and investor outlook."
      },
      {
        "title": "Ajanta Pharma Q4 FY26: Strong Topline Growth Masks Margin Pressure Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/ajanta-pharma-q4-fy26-strong-topline-growth-masks-margin-pressure-concerns-3976507",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AjantaPharma_quaterlyResult_3976507.png",
        "date": "2026-05-05 21:45:33",
        "description": "Ajanta Pharma Ltd., a specialty pharmaceutical formulations company with operations across India, Asia, and Africa, reported a mixed performance for the quarter ended March 2026, with robust revenue growth offset by declining profitability on a sequential basis. The company posted a consolidated net profit of ₹266.70 crores for Q4 FY26, representing a marginal decline of 2.58% quarter-on-quarter but a healthy gain of 18.40% year-on-year. With a market capitalisation of ₹36,144 crores, the stock traded at ₹2,900.90 as of May 05, 2026, down 0.11% from the previous close."
      },
      {
        "title": "Ajanta Pharma Ltd. Exhibits Mildly Bullish Momentum Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-exhibits-mildly-bullish-momentum-amid-mixed-technical-signals-3969349",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AjantaPharmaLtd_technicaldot_3969349.png",
        "date": "2026-04-30 08:00:26",
        "description": "Ajanta Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a mixed bag of technical indicator signals, the stock’s price action and relative strength suggest cautious optimism for investors navigating the current market environment."
      },
      {
        "title": "Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-3967357",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AjantaPharmaLtd_technicaldot_3967357.png",
        "date": "2026-04-29 08:00:26",
        "description": "Ajanta Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture, with bearish signals on weekly and monthly MACD and KST, while moving averages and Bollinger Bands offer mixed cues. This article analyses these technical developments in detail, placing them in the context of the stock’s recent price action and relative performance against the Sensex."
      },
      {
        "title": "Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-hold-by-marketsmojo-3963060",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AjantaPharmaLtd_mojoScore_3963060.png",
        "date": "2026-04-26 10:10:24",
        "description": "Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 March 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the company’s current position as of 26 April 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook."
      }
    ],
    "total": 644,
    "sid": "178818",
    "stock_news_url": "https://www.marketsmojo.com/news/ajanta-pharma-178818"
  },
  "announcements": [
    {
      "details": "Ajanta Pharma Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI ( LODR) , 2015.",
      "source": "NSE",
      "caption": "Ajanta Pharma Limited - Other General Purpose",
      "datetime": "27-Nov-2019"
    },
    {
      "details": "Ajanta Pharma Limited has informed the Exchange regarding Investor Presentation",
      "source": "NSE",
      "caption": "Ajanta Pharma Limited - Investor Presentation",
      "datetime": "06-Nov-2019"
    },
    {
      "details": "Ajanta Pharma Limited has informed the Exchange that the Company has fixed Record Date as November 18, 2019 for the purpose of Interim dividend",
      "source": "NSE",
      "caption": "Ajanta Pharma Limited - Record Date",
      "datetime": "23-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has declared <strong>1400%</strong> dividend, ex-date: 10 Nov 25",
          "dt": "2025-11-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>2:5</strong> stock split, ex-date: 20 Mar 15",
          "dt": "2015-03-20",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>1:2</strong> bonus issue, ex-date: 22 Jun 22",
          "dt": "2022-06-22",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ajanta Pharma Gains 4.41%: Key Events and Market Dynamics from 4-8 May 2026

2026-05-10 15:00:04

Key Events This Week

4 May: Week opens at Rs.2,904.15

5 May: Q4 FY26 results reveal strong topline but margin concerns

6 May: Intraday high surge to Rs.3,111.5 (+7.24%)

7 May: Slight pullback to Rs.3,080.20 (-0.42%)

8 May: Week closes at Rs.3,032.20 (-1.56%)

Week Open

Rs.2,904.15

W...

Read full news article

Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO

2026-05-07 10:10:27

Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Are Ajanta Pharma Ltd. latest results good or bad?

2026-05-06 19:15:51

Ajanta Pharma Ltd. reported its Q4 FY26 results, showcasing a strong revenue performance alongside some concerns regarding profitability. The company achieved net sales of ₹1,421.64 crores, reflecting a year-on-year growth of 21.47%, which is significantly higher than the previous year's growth of 11.04%. This marks the highest quarterly revenue in the company's history, indicating robust demand and effective market strategies. However, the financial results also revealed challenges in maintaining profitability. The net profit for the quarter stood at ₹266.70 crores, representing an 18.40% increase year-on-year, yet it experienced a sequential decline of 2.58% from the previous quarter. This decline raises questions about the sustainability of profit levels despite strong sales growth. A notable concern is the contraction in operating margins, which fell to 23.45% from 27.80% in the previous quarter, indi...

Read full news article

Ajanta Pharma Ltd. Surges 7.24% to Day's High of Rs 3111.5 — Outperforms Sector by 4.72 Percentage Points

2026-05-06 12:45:49

The Sensex edged lower by 0.12% on 6 May 2026, while Ajanta Pharma Ltd. surged 7.24%, touching an intraday high of Rs 3111.5. This 4.72-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.14% gain highlights a distinctly stock-specific rally rather than a broad market lift.

Read full news article

Ajanta Pharma Reports Flat Quarterly Performance Amidst Strong Historical Returns

2026-05-06 08:00:05

Ajanta Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. Despite achieving its highest-ever quarterly net sales, the company’s overall financial trend score has declined, prompting a reassessment of its market stance and investor outlook.

Read full news article

Ajanta Pharma Q4 FY26: Strong Topline Growth Masks Margin Pressure Concerns

2026-05-05 21:45:33

Ajanta Pharma Ltd., a specialty pharmaceutical formulations company with operations across India, Asia, and Africa, reported a mixed performance for the quarter ended March 2026, with robust revenue growth offset by declining profitability on a sequential basis. The company posted a consolidated net profit of ₹266.70 crores for Q4 FY26, representing a marginal decline of 2.58% quarter-on-quarter but a healthy gain of 18.40% year-on-year. With a market capitalisation of ₹36,144 crores, the stock traded at ₹2,900.90 as of May 05, 2026, down 0.11% from the previous close.

Read full news article

Ajanta Pharma Ltd. Exhibits Mildly Bullish Momentum Amid Mixed Technical Signals

2026-04-30 08:00:26

Ajanta Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a mixed bag of technical indicator signals, the stock’s price action and relative strength suggest cautious optimism for investors navigating the current market environment.

Read full news article

Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-04-29 08:00:26

Ajanta Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture, with bearish signals on weekly and monthly MACD and KST, while moving averages and Bollinger Bands offer mixed cues. This article analyses these technical developments in detail, placing them in the context of the stock’s recent price action and relative performance against the Sensex.

Read full news article

Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO

2026-04-26 10:10:24

Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 March 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the company’s current position as of 26 April 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Read full news article

View All News